Oncology & Cancer

Immune system infighting explains pancreatic cancer's aggression

Internal conflict between cell types explains why the immune system struggles to recognize and attack pancreatic cancer. Curbing this infighting has the potential to make treatment more effective, according to a study led ...

Oncology & Cancer

EGFR essential for the development of pancreatic cancer

The epidermal growth factor receptor (EGFR) gene is essential for KRAS-driven pancreatic cancer development, according to study results presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, ...

Oncology & Cancer

Early biomarker for pancreatic cancer identified

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently ...

Oncology & Cancer

Variation in cancer-causing KRAS mutations greater than thought

The effects of KRAS mutations underlying many different types of cancer are more diverse than previously thought, according to a new study led by the University of Eastern Finland. Different mutations in the same amino acid ...

Oncology & Cancer

Targeting pancreatic cancer through signalling

Researchers have identified a new way to tailor treatments for patients with pancreatic cancer, one of the most deadly forms of cancer. Currently only five per cent of people with pancreatic cancer survive longer than five ...

Oncology & Cancer

Organoid profiling identifies treatments for pancreatic cancer

Patient-derived organoids, hollow spheres of cells cultured from tumors, can quickly and accurately predict how patients with pancreatic cancer respond to a variety of treatments, facilitating a precision-medicine approach ...

page 4 from 9